These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 11498718

  • 1. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
    Fattore L, Cossu G, Martellotta CM, Fratta W.
    Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
    [Abstract] [Full Text] [Related]

  • 2. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
    McMahon LR.
    Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
    [Abstract] [Full Text] [Related]

  • 3. CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats.
    Fattore L, Martellotta MC, Cossu G, Mascia MS, Fratta W.
    Behav Brain Res; 1999 Oct; 104(1-2):141-6. PubMed ID: 11125733
    [Abstract] [Full Text] [Related]

  • 4. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat.
    Spano MS, Fattore L, Cossu G, Deiana S, Fadda P, Fratta W.
    Br J Pharmacol; 2004 Oct; 143(3):343-50. PubMed ID: 15339858
    [Abstract] [Full Text] [Related]

  • 5. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice.
    Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W.
    Neuroscience; 1998 Jul; 85(2):327-30. PubMed ID: 9622233
    [Abstract] [Full Text] [Related]

  • 6. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.
    Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR.
    J Pharmacol Exp Ther; 2003 Jul; 306(1):93-102. PubMed ID: 12660305
    [Abstract] [Full Text] [Related]

  • 7. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats.
    Fattore L, Spano S, Cossu G, Deiana S, Fadda P, Fratta W.
    Neuropharmacology; 2005 Jun; 48(8):1097-104. PubMed ID: 15910886
    [Abstract] [Full Text] [Related]

  • 8. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
    Pan X, Ikeda SR, Lewis DL.
    Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635
    [Abstract] [Full Text] [Related]

  • 9. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
    McMahon LR, Koek W.
    Eur J Pharmacol; 2007 Aug 13; 569(1-2):70-6. PubMed ID: 17553486
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function.
    Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W.
    Br J Pharmacol; 2007 Nov 13; 152(5):795-804. PubMed ID: 17891164
    [Abstract] [Full Text] [Related]

  • 13. Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking.
    Gamaleddin I, Wertheim C, Zhu AZ, Coen KM, Vemuri K, Makryannis A, Goldberg SR, Le Foll B.
    Addict Biol; 2012 Jan 13; 17(1):47-61. PubMed ID: 21521420
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation.
    Niederhoffer N, Szabo B.
    Br J Pharmacol; 1999 Jan 13; 126(2):457-66. PubMed ID: 10077239
    [Abstract] [Full Text] [Related]

  • 16. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
    Darmani NA.
    Eur J Pharmacol; 2001 Oct 26; 430(1):49-58. PubMed ID: 11698062
    [Abstract] [Full Text] [Related]

  • 17. Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats.
    Mendiguren A, Pineda J.
    Eur J Pharmacol; 2006 Mar 18; 534(1-3):83-8. PubMed ID: 16483566
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.
    Lefever TW, Marusich JA, Antonazzo KR, Wiley JL.
    Pharmacol Biochem Behav; 2014 Mar 18; 118():30-5. PubMed ID: 24412835
    [Abstract] [Full Text] [Related]

  • 19. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats.
    Chaperon F, Soubrié P, Puech AJ, Thiébot MH.
    Psychopharmacology (Berl); 1998 Feb 18; 135(4):324-32. PubMed ID: 9539255
    [Abstract] [Full Text] [Related]

  • 20. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A.
    Gifford AN, Ashby CR.
    J Pharmacol Exp Ther; 1996 Jun 18; 277(3):1431-6. PubMed ID: 8667207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.